Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Role of CD4/6 Inhibitors in Breast Cancer Treatment.
Purohit L, Jones C, Gonzalez T, Castrellon A, Hussein A. Purohit L, et al. Among authors: castrellon a. Int J Mol Sci. 2024 Jan 19;25(2):1242. doi: 10.3390/ijms25021242. Int J Mol Sci. 2024. PMID: 38279242 Free PMC article. Review.
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. Gelmon KA, et al. Among authors: castrellon a. Breast J. 2020 Mar;26(3):368-375. doi: 10.1111/tbj.13516. Epub 2019 Aug 25. Breast J. 2020. PMID: 31448513 Free PMC article. Clinical Trial.
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Rugo HS, Finn RS, Gelmon K, Joy AA, Harbeck N, Castrellon A, Mukai H, Walshe JM, Mori A, Gauthier E, Lu DR, Bananis E, Martin M, Diéras V. Rugo HS, et al. Among authors: castrellon a. Clin Breast Cancer. 2020 Apr;20(2):e173-e180. doi: 10.1016/j.clbc.2019.08.009. Epub 2019 Sep 5. Clin Breast Cancer. 2020. PMID: 31836434 Free article. Clinical Trial.
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).
Hurvitz S, Singh R, Adams B, Taguchi JA, Chan D, Dichmann RA, Castrellon A, Hu E, Berkowitz J, Mani A, DiCarlo B, Callahan R, Smalberg I, Wang X, Meglar I, Martinez D, Hobbs E, Slamon DJ. Hurvitz S, et al. Among authors: castrellon a. Ther Adv Med Oncol. 2018 Nov 9;10:1758835918807339. doi: 10.1177/1758835918807339. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30542377 Free PMC article.
A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA, Liggett W, Mainwaring M, Castrellon A, Blakely L, Hemphill B, Anz B 3rd, Young RR, Shastry M, DeBusk LM, Hainsworth JD, Burris HA 3rd. Yardley DA, et al. Among authors: castrellon a. Clin Breast Cancer. 2020 Apr;20(2):89-97. doi: 10.1016/j.clbc.2019.06.005. Epub 2019 Jun 26. Clin Breast Cancer. 2020. PMID: 31932237 Clinical Trial.
Chemoprevention of breast cancer.
Castrellon AB, Glück S. Castrellon AB, et al. Expert Rev Anticancer Ther. 2008 Mar;8(3):443-52. doi: 10.1586/14737140.8.3.443. Expert Rev Anticancer Ther. 2008. PMID: 18366291 Review.
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. Rugo HS, et al. Among authors: castrellon a. Breast Cancer Res Treat. 2019 Apr;174(3):719-729. doi: 10.1007/s10549-018-05125-4. Epub 2019 Jan 10. Breast Cancer Res Treat. 2019. PMID: 30632023 Free PMC article. Clinical Trial.
24 results